Vericel (VCEL) Expected to Announce Earnings on Thursday

Vericel (NASDAQ:VCEL - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of $0.31 per share and revenue of $76.47 million for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.

Vericel Price Performance

Shares of Vericel stock traded down $2.31 during trading on Friday, hitting $52.00. The stock had a trading volume of 414,572 shares, compared to its average volume of 321,010. The firm's fifty day simple moving average is $57.64 and its 200-day simple moving average is $51.58. The stock has a market cap of $2.57 billion, a PE ratio of 866.81 and a beta of 1.72. Vericel has a 12 month low of $39.12 and a 12 month high of $63.00.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. BTIG Research raised their price objective on shares of Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research note on Tuesday, December 24th. Canaccord Genuity Group raised their price target on Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Stephens reiterated an "overweight" rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $60.00 target price on shares of Vericel in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $63.14.

Insiders Place Their Bets

In related news, insider Jonathan Mark Hopper sold 10,000 shares of the company's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $58.72, for a total value of $587,200.00. Following the completion of the sale, the insider now directly owns 58,371 shares of the company's stock, valued at $3,427,545.12. This represents a 14.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Siegal sold 1,092 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total transaction of $67,693.08. Following the completion of the sale, the insider now directly owns 1,206 shares of the company's stock, valued at $74,759.94. The trade was a 47.52 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,100 shares of company stock worth $1,206,072. 5.20% of the stock is currently owned by company insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.